![](images/d09566b118c7b41e7802b55d14386a9d39940a2a5b2159407e664830945e1c64.jpg)

# Comparison of Assays--Similarities and Differences

Feature

# Elecsys HE4 Assay

<table><tr><td rowspan=1 colspan=1>IntendedUse/Indicationsfor Use</td><td rowspan=1 colspan=1>The Elecsys HE4 assay is animmunoassay for the quantitativedetermination of HE4 in human serumand plasma. The assay is used as an aidin monitoring the recurrence orprogressive disease in patients withepithelial ovarian cancer. Serial testingfor patient HE4 assay values should beused in conjunction with other clinicalfindings used for monitoring ovariancancer.The electrochemiluminescenceimmunoassay &quot;ECLIA&quot; is intended foruse on Elecsys and cobas e immunoassayanalyzers.</td><td rowspan=1 colspan=1>The ARCHITECT HE4 assay is achemiluminescent microparticleimmunoassay (CMIA) for the quantitativedetermination of the HE4 antigen inhuman serum.The assay is to be used as an aid inmonitoring recurrence or progressivedisease in patients with epithelial ovariancancer. Serial testing for patient HE4assay values should be used inconjunction with other clinical methodsused for monitoring epithelial ovariancancer.</td></tr><tr><td rowspan=1 colspan=1>AssayProtocol</td><td rowspan=1 colspan=1>Quantitative sandwich immunoassay</td><td rowspan=1 colspan=1>Quantitative chemiluminsecentmicroparticle immunometric assay</td></tr><tr><td rowspan=1 colspan=1>DetectionProtocol</td><td rowspan=1 colspan=1>Electrochemiluminescence</td><td rowspan=1 colspan=1>Chemiluminescence</td></tr><tr><td rowspan=1 colspan=1>Applications</td><td rowspan=1 colspan=1>18 minute application</td><td rowspan=1 colspan=1>Not reported</td></tr></table>

Continued on next page

# 510(k) Summary

Continued

# Comparison of Assays—Similarities and Differences, continued

Continued on next page   

<table><tr><td rowspan=1 colspan=3>munoassay.Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys HE4 Assay</td><td rowspan=1 colspan=1>Predicate Device: Abbott Architecthi $ HE4 (K093957)</td></tr><tr><td rowspan=1 colspan=3>General Assay Features</td></tr><tr><td rowspan=1 colspan=1>InstrumentPlatform</td><td rowspan=1 colspan=1>Elecsys 2010 and MODULARANALYTICS E170; Cobas e 411, cobas e601 and cobas e 602</td><td rowspan=1 colspan=1>ARCHITECT i 2000, i 2000sR, i 1000 andi1000sR.</td></tr><tr><td rowspan=1 colspan=1>SampleVolume</td><td rowspan=1 colspan=1>10 μL</td><td rowspan=1 colspan=1>75 µL for first test plus 25 µL for eachadditional test from the same sample cup.≤ 3 hours on board: 150 μL for the firsttest plus 25 μL for each additional testfrom the same sample cup.</td></tr><tr><td rowspan=1 colspan=1>SampleType</td><td rowspan=1 colspan=1>Human serum and plasma treated withK2-EDTA, K3-EDTA or lithium heparin.</td><td rowspan=1 colspan=1>Human serum</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>The Elecsys HE4 assay is a sandwichimmunoassay which includes abiotinylated monoclonal, murine HE4-specific IgG antibody as capture and aruthenium labeled monoclonal, murineHE4-specific IgG antibody as signal.</td><td rowspan=1 colspan=1>The Abbott ARCHITECT HE4 is a two-step immunoassay for the quantitativedetermination of HE4 antigen in humanserum using CMlA technology withflexible assay protocols, referred to asChemiflex.</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Elecsys HE4 CalSet, 2 levels</td><td rowspan=1 colspan=1>Abbott ARCHITECT HE4 Calibrators, 6levels</td></tr></table>

# 510(k) Summary

Continued

# Comparison of Assays—Similarities and Differences, continued

<table><tr><td colspan="3">Immunoassay Comparison tv</td></tr><tr><td>Fea</td><td colspan="2">Predicate Devices: Abbott Architect $ Elecsys HE4 Assay HE4 (K093957)</td></tr><tr><td colspan="3">General Assay Features</td></tr><tr><td>Calibration Interval</td><td>Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the reagent kit was registered on the analyzer). Renewed calibration is recommended as follows: After 28 days when using the same reagent lot. After 7 days (when using the</td><td>Once an ARCHITECT HE4 calibration is accepted and stored, all subsequent samples may be tested without further calibration unless onr or more of the following occur: A reagent kit with a new lot number is used Controls are out of range •</td></tr><tr><td>Controls</td><td>same reagent kit on the analyzer). As required: e.g. quality control findings outside the specified limits Elecsys HE4 PreciControl</td><td>Abbott ARCHITECT HE4 Controls</td></tr></table>

Continued on next page

# 510(k) Summary

Continued

# Comparison of Assays—Similarities and Differences, continued

<table><tr><td rowspan=1 colspan=3>Immunoassay Comparison                  1</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>3Elecsys HE4 Assay</td><td rowspan=1 colspan=1>Predicate Device: AbbottArchitect HE4 (K093957)</td></tr><tr><td rowspan=1 colspan=3>General assay features. g </td></tr><tr><td rowspan=1 colspan=1>Traceability /Standardization</td><td rowspan=1 colspan=1>The Elecsys HE4 Assay has becnstandardized against the HE4 EIA methodfrom Fujirebio Diagnostics, Inc.</td><td rowspan=1 colspan=1>Not reported</td></tr><tr><td rowspan=1 colspan=1>ReagentStability</td><td rowspan=1 colspan=1>Unopened at 2-8 °C—up to statedexpiration dateAfter opening at 2-8 °C—12 weeksOn the analyzers—28 days</td><td rowspan=1 colspan=1>The ARCHITECT HE4 Reagent Kitmust be stored at 2-8°C in an uprightposition and may be used immediatelyafter removal from 2-8°C.When stored and handled as directed,the reagents are stable until theexpiration date.The ARCHITECT HE4 Reagent Kitmay be stored on board theARCHITECT i System for a maximumof 30 days.Reagents may be stored on or off theARCHITECT i system. If reagents areremoved from the system, store them at2-8°C (with septums and replacementcaps) in an upright position. For . .reagents stored off the system, it isrecommended that they be stored intheir original trays and boxes to ensurethey remain upright. If themicroparticle bottle does not remainupright (with a septum installed) whilein refrigerated storage off the system,the reagent kit must be discarded.</td></tr></table>

Continued on next page

# 510(k) Summary

Continued

# Comparison of Assays—Similarities and Differences, continued

<table><tr><td rowspan=1 colspan=3>As        Immunoassay Comparison                                     &quot;d)*&quot;</td></tr><tr><td rowspan=1 colspan=1>*Feature</td><td rowspan=1 colspan=1>Elecsys HE4 Assay</td><td rowspan=1 colspan=1>Predicate Dévice: Abbott ArchitectHE4 (K093957)     .</td></tr><tr><td rowspan=1 colspan=3>Labeled Perf  mance Characteristics</td></tr><tr><td rowspan=1 colspan=1>MeasuringRange</td><td rowspan=1 colspan=1>15-1,5000 pmol/L</td><td rowspan=1 colspan=1>20-1,500 pmol/L</td></tr><tr><td rowspan=4 colspan=1>Precision</td><td rowspan=1 colspan=1>Elecsys 2010/ cobas e 411:Within-run (will be labclcd Repeatability)n}=841.8% CV @   25.3 pmol/L1.4% CV @   45.7 pmol/L1.8% CV @   53.7 pmol/L1.6% CV @   142.0pmol/L1.6% CV @   345.0pmol/L1.5% CV @   779.0pmol/L1.3% CV @   1437.0 pmol/LTotal (will be labeled Intermediate)3.7% CV @   25.3 pmol/L</td><td rowspan=4 colspan=1>On the ARCHITECT i 2000sR System:Within-runn=803.0% CV @   49.0 pmol/L2.2% CV @   174.4 pmol/L2.4% CV @   687.3 pmol/L3.1% CV @   38.4 pmol/L2.9% CV @   189.7 pmol/L2.9% CV @   1114.7 pmol/LTotal3.3% CV @   49.0 pmol/L3.1% CV @    174.4 pmol/L3.3% CV @   687.3 pmol/L3.8% CV @   38.4 pmol/L3.1% CV @   189.7 pmol/L3.3% CV @   1114.7 pmol/L</td></tr><tr><td rowspan=2 colspan=1>4.2% CV @   45.7 pmol/L4.2% CV @   53.7 pmol/L</td><td rowspan=1 colspan=1>3.3% CV @</td></tr><tr><td rowspan=1 colspan=1>3.1% CV @</td></tr><tr><td rowspan=1 colspan=1>4.3% CV @   142.0pmol/L3.4% CV @   345.0pmol/L2.7% CV @   779.0 pmol/L4.2% CV @   1437.0 pmol/L</td></tr></table>

# 510(k) Summary

Continued

# Comparison of Assays-Similarities and Differences, continued

<table><tr><td rowspan=1 colspan=6>                                 6.       Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>2.46Feature</td><td rowspan=1 colspan=4>Elecsys HE4 Assay</td><td rowspan=1 colspan=1>Predicate Device: Abbott Architect  HE4 (K093957)</td></tr><tr><td rowspan=1 colspan=6>&quot; prlLabeled Performance Characteristics.      &quot;dey</td></tr><tr><td rowspan=1 colspan=1>AnalyticalSensitivity</td><td rowspan=1 colspan=4>On the e411:Limit of Blank (LoB) 5.0 pmol/LLimit of Detection (LoD) 15.0 pmol/LLimit of Quantitation (LoQ) 20.0 pmol/Lwith a total allowable error of 30%</td><td rowspan=1 colspan=1>Limit of Blank: 0.1 pmol/LLimit of Detection: ≤ 15 pmol/LFunctional Sensitivity: 20 pmol/L</td></tr><tr><td rowspan=5 colspan=1>AnalyticalSpecificity</td><td rowspan=1 colspan=4></td><td rowspan=5 colspan=1>No cross reaclivity of above +/- LoD (&lt;15pmol/L) was seen with the followinginterferents tested:•  CA 125•  CA 15-3•  CA 19-9•  CEA•  AFP</td></tr><tr><td></td><td rowspan=1 colspan=1>Proteins (WFDCfamily</td><td rowspan=1 colspan=1>Reactivity</td><td></td></tr><tr><td></td><td rowspan=1 colspan=1>Elafin/ SKALPat 54,500 pmol/L</td><td rowspan=1 colspan=1>0.025%</td><td></td></tr><tr><td rowspan=1 colspan=2>SLPI at 20,833pmol/L</td><td rowspan=1 colspan=1>0.088</td><td></td></tr><tr><td rowspan=1 colspan=4></td></tr><tr><td rowspan=1 colspan=1>Hook Effect</td><td rowspan=1 colspan=4>There is no high-dose hook effect at HE4concentrations up to 40,000 pmol/L.</td><td rowspan=1 colspan=1>There is no high-dose hook effect at HE4concentrations up to 83,000 pmol/L.</td></tr></table>

Continued on next page

# 510(k) Summary

Continued

# Comparison of Assays—Similarities and Differences, continued

<table><tr><td rowspan=1 colspan=3>5           44A    munoassay ComparisonE           ,&#x27;4s&#x27;                     ERA</td></tr><tr><td rowspan=1 colspan=1>Feature, LF4</td><td rowspan=1 colspan=1>Elecsys HE4 Assay  ajia</td><td rowspan=1 colspan=1>Predicate Device: Abbott ArchitectHE4 (K093957)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Labeled Performance Characteristics</td></tr><tr><td rowspan=4 colspan=1>Limitations</td><td rowspan=4 colspan=1>The assay is unaffected by:Hemoglobin ≤ 1.0 g/dLBilirubin up ≤ 66 mg/dLTriglycerides ≤ 2,000 mg/dLBiotin ≤ 50 ng/mLRheumatoid Factor &lt; 1,500 IU/mLHAMA &lt; 805 ng/mLIgG ≤ 70 g/LIn vitro tests were performed on 52commonly used pharmaceuticals. Nointerference with the assay was found.In rare cases, interference due toextremely high titers of antibodies toanalyte-specific antibodies (such asHAMA), streptavidin or rutheniumcan occur. These effects areminimized by suitable test design.</td><td rowspan=1 colspan=1>The assay is unaffected by:Hemoglobin 500 mg/dLBilirubin up 20 mg/dLTriglycerides 3000 mg/dLLow protein 3 g/dLHigh protein 12 g/dLSix specimens positive for HAMA and sixspecimens positive for Rheumatoid Factor(RF) were evaluated at the indicatedinterferent concentration ranges. The dataare summarized in the following table.</td></tr><tr><td rowspan=1 colspan=1>Mean %Recovery</td></tr><tr><td rowspan=1 colspan=1>102</td></tr><tr><td rowspan=1 colspan=1>103</td></tr></table>

# 510(k) Summary

Continued

# Comparison of Assays—Similarities and Differences, continued

<table><tr><td rowspan=1 colspan=5>Immunoassay Comparison·ty</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=3>Elecsys HE4 Assay</td><td rowspan=1 colspan=1>Predicate Device: Abbott ArchitectHE4 (K093957)</td></tr><tr><td rowspan=1 colspan=5>Labeled Performance Characteristicsa</td></tr><tr><td rowspan=1 colspan=1>ClinicalSensitivityandSpecificity</td><td rowspan=1 colspan=3>See below</td><td rowspan=1 colspan=1>Sce below</td></tr><tr><td rowspan=7 colspan=1>InternalMethodComparison(cobas e 601vs. cobas e411)</td><td rowspan=7 colspan=4>n = 131                         Passing/Bablok          Linear RegressionMin = 17.0 pmol/LMax = 1405.0 pmol/LSlope                                      1.01                       1.00(1.00-1.02)             (0.994-1.01)Intercept                                 -0.435                     2.29(-1.03-0.365)             (1.01-3.56)Tau/r                                     0.979                     0.999</td></tr><tr><td rowspan=1 colspan=1>n = 131</td><td rowspan=3 colspan=1>Passing/Bablok</td><td rowspan=3 colspan=1>Linear Regression</td></tr><tr><td rowspan=1 colspan=1>Min = 17.0 pmol/L</td></tr><tr><td rowspan=1 colspan=1>Max = 1405.0 pmol/L</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>1.01(1.00-1.02)</td><td rowspan=1 colspan=1>1.00(0.994-1.01)</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>-0.435(-1.03-0.365)</td><td rowspan=1 colspan=1>2.29(1.01-3.56)</td></tr><tr><td rowspan=1 colspan=1>Tau/r</td><td rowspan=1 colspan=1>0.979</td><td rowspan=1 colspan=1>0.999</td></tr></table>

# 510(k) Summary

Continued

Clinical Sensitivity and Specificity Elecsys HE4   

<table><tr><td rowspan=1 colspan=1>PercentChangein HE4</td><td rowspan=1 colspan=1>Sensitivity(%)(n/N)</td><td rowspan=1 colspan=1>Lower Cl(95%) forSensitivity</td><td rowspan=1 colspan=1>Upper CI(95 %) forSensitivity</td><td rowspan=1 colspan=1>Specificity (%)(n/N)</td><td rowspan=1 colspan=1>Lower CI(95%) forSpecificity</td><td rowspan=1 colspan=1>Upper CI(95%) forSpecificity</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69.14 (56/81)</td><td rowspan=1 colspan=1>57.61</td><td rowspan=1 colspan=1>80.88</td><td rowspan=1 colspan=1>57.83(192/332)</td><td rowspan=1 colspan=1>52.35</td><td rowspan=1 colspan=1>63.44</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>62.96 (51/81)</td><td rowspan=1 colspan=1>50.63</td><td rowspan=1 colspan=1>75.61</td><td rowspan=1 colspan=1>68.07(226/332)</td><td rowspan=1 colspan=1>62.71</td><td rowspan=1 colspan=1>73.08</td></tr><tr><td rowspan=1 colspan=1>10.</td><td rowspan=1 colspan=1>54.32 (44/81)</td><td rowspan=1 colspan=1>42.13</td><td rowspan=1 colspan=1>66.67</td><td rowspan=1 colspan=1>74.70(248/332)</td><td rowspan=1 colspan=1>69.47.</td><td rowspan=1 colspan=1>79.32</td></tr><tr><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>50.62 (41/81)</td><td rowspan=1 colspan=1>39.34</td><td rowspan=1 colspan=1>62.09</td><td rowspan=1 colspan=1>77.41(257/332)</td><td rowspan=1 colspan=1>72.52</td><td rowspan=1 colspan=1>81.76 </td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>49.38 (40/81)</td><td rowspan=1 colspan=1>38.28</td><td rowspan=1 colspan=1>60.48</td><td rowspan=1 colspan=1>78.31(260/332)</td><td rowspan=1 colspan=1>73.68</td><td rowspan=1 colspan=1>82.51</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>46.91 (38/81)</td><td rowspan=1 colspan=1>.35.44</td><td rowspan=1 colspan=1>58.44</td><td rowspan=1 colspan=1>84.04(279/332)</td><td rowspan=1 colspan=1>80.12</td><td rowspan=1 colspan=1>87.76</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>39.51 (32/81)</td><td rowspan=1 colspan=1>28.84</td><td rowspan=1 colspan=1>51.23</td><td rowspan=1 colspan=1>87.05(289/332)</td><td rowspan=1 colspan=1>.83.56</td><td rowspan=1 colspan=1>90.34</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>24.69 (20/81)</td><td rowspan=1 colspan=1>16.00</td><td rowspan=1 colspan=1>34.52</td><td rowspan=1 colspan=1>95.78(318/332)</td><td rowspan=1 colspan=1>93.65</td><td rowspan=1 colspan=1>97.64</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>17.28 (14/81)</td><td rowspan=1 colspan=1>9.20</td><td rowspan=1 colspan=1>26.75</td><td rowspan=1 colspan=1>97.59(324/332)</td><td rowspan=1 colspan=1>95.92</td><td rowspan=1 colspan=1>99.02</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>14.81 (12/81)</td><td rowspan=1 colspan=1>7.50</td><td rowspan=1 colspan=1>23.94</td><td rowspan=1 colspan=1>97.89(325/332)</td><td rowspan=1 colspan=1>96.29</td><td rowspan=1 colspan=1>99.19</td></tr></table>

# 510(k) Summary

Continued

Clinical Sensitivity and Specificity ARCHITECT HE4   

<table><tr><td rowspan=1 colspan=1>PercentChange inHE4</td><td rowspan=1 colspan=1>Sensitivity(%)</td><td rowspan=1 colspan=1>Specificity(%)</td><td rowspan=1 colspan=1>PPV (%)</td><td rowspan=1 colspan=1>NPV (%)</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>85</td></tr><tr><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>54a</td><td rowspan=1 colspan=1>79b</td><td rowspan=1 colspan=1>43c</td><td rowspan=1 colspan=1>85d</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>85</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>83</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>82</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>80</td></tr></table>

a. Sensitivity is $1 0 0 \mathrm { X }$ (number of sequential pairs with $a \geq 1 4 \%$ increase in HE4 concentration from patients with disease progression/total number of sequential pairs from patients with disease progression)   
b. Specificity is $1 0 0 \mathrm { X }$ (number of sequential pairs with $< 1 4 \%$ increase in HE4 concentration . from patients without disease progression/total number of sequential pairs from patients without disease progression)   
C. PPV = 100 X(number of sequential pairs with ≥ 14% increase in HE4 concentration from patients with discase progression/total number of sequential pairs with a ≥ 14% increase in HE4 concentration)   
d. $\mathbf { \ddot { N P V } } = 1 0 0 ~ \mathbf { X }$ (number of sequential pairs with $< 1 4 \%$ increase in HE4 concentration from patients without disease progression/total number of sequential pairs with a < 14% increase in HE4 concentration)

# 510(k) Summary

Continued

# Comparison of Calibrator Materials

<table><tr><td rowspan=1 colspan=1>Characteristicauna&quot;</td><td rowspan=1 colspan=1>1} CalSet for Elecsys HE4 Assay</td><td rowspan=1 colspan=1>Predicate Device: Elecsys hGH;      CalSet (K103221) *-</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Elecsys HE4 CalSet is used forcalibrating the quantitative ElecsysHE4 assay on the Elecsys and cobas eimmunoassay analyzers.</td><td rowspan=1 colspan=1>Elecsys hGH CalSet is used forcalibrating the quantitative ElecsyshGH assay on the Elecsys andcobas e immunoassay analyzers.</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Two</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Equine serum</td><td rowspan=1 colspan=1>Human serum</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened:Store at 2 - 8°C up to the statedexpiration date.After reconstitution:At 2 - 8°C: 7 days.At -20°C: 8 weeks (freeze onlyonce).On Elecsys 2010/cobas e 411 at 20- 25°C: Up to 5 hours.On MODULAR ANALYTICSE170/cobas e 601 and 602: Useonly once.</td><td rowspan=1 colspan=1>Unopened:Store at 2 - 8°C up to the statedexpiration date.After reconstitution:At 2 - 8°C: 7 daysAt -20°C: 28 days (freeze onlyonce).On Elecsys 2010/cobas e 411 at20 - 25°C: Up to 5 hours.On MODULAR ANALYTICSE170/cobas e 601: Use only once.</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Dissolve the contents of one bottlecarefully by adding exactly 1.0 mL ofdistilled water and allow to standclosed for 15 minutes to reconstitute.Mix carefully, avoiding the formationof foam. Transfer the reconstitutedcalibrator into the empty labeled snap-cap bottles supplied.</td><td rowspan=1 colspan=1>Dissolve carefully the contents ofone bottle by adding exactly 1.0 mLof distilled or deionized water andallow to stand closed for 15 minutesto reconstitute. Mix carefully,avoiding the formation of foam.Transfer the reconstituted calibratorinto the empty labeled snap-capbottle supplied.</td></tr></table>

# 510(k) Summary

Continued

# Comparison of PreciControl Materials

<table><tr><td></td><td></td><td rowspan=2 colspan=1>Predicate Device:Elecsys PreciControlMultimarker (K102157)  S</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>y aElecsys HE4 PreciControl2r</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Elecsys PreciControl HE4 is used forquality control of Elecsys HE4 on theElecsys and cobas e immunoassayanalyzers.</td><td rowspan=1 colspan=1>Elecsys PreciControl Multimarker isused for quality control of specifiedElecsys immunoassays on the Elecsysand cobas e immunoassay analyzers.</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Two</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AnalyteConcentration</td><td rowspan=1 colspan=1>Approximately 50 and 400 pmol/L</td><td rowspan=1 colspan=1>C-Peptide (synthetic): Approximately2 and 10 ng/mL.Insulin (human recombinant fromyeast): Approximalely 25 and 80μU/mL.ACTH (synthetic): Approximately 50and 1,000 pg/mL.hGH (human recombinant from E.coli): Approximately 1 and 10 ng/mL.</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened:Store at 2-8°C up to the statedexpiration date.Reconstituted:2 - 8°C: 14 days-20°C: 4 weeks (freeze only once)On the analyzers at 20-25°C: up to 5hoursAt 20-25°C: 24 hours</td><td rowspan=1 colspan=1>Unopened:Store at 2-8°C up to the statedexpiration date.Reconstituted:2 - 8°C: 72 hours-20°C: 31 days (freeze only once)On the analyzers at 20-25°C: up to5 hours</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Carefully dissolve the contents of onebottle by adding exactly 1.0 mL ofdistilled or deionized water and allow tostand closed for 15 minutes toreconstitute. Mix carefully, avoiding theformation of foam. Transfer thereconstituted control into the empty,labeled snap-cap bottles supplied orfreeze aliquots in additional snap-capbottles (ControlSet Vials). Attach thesupplied labels to these bottles. Performonly one control procedure per aliquot.</td><td rowspan=1 colspan=1>Dissolve carefully the contents of onebottle by adding exactly 2.0 mL ofdistilled or deionized water and allowto stand closed for 30 minutes toreconstitute. Mix carefully, avoidingthe formation of foam. Transfer thereconstituted control into empty,labeled snap-cap bottles supplied(ControlSet Vials) and freeze aliquotsimmediately in additional ControlSetVials. Attach the supplied labels tothese additional bottles. Perform onlyone control procedure per aliquot.</td></tr></table>

Continued on next page

# 510(k) Summary

Continued

# Comparison of CalCheck 5 Materials

<table><tr><td rowspan=1 colspan=1>        :Characteristic       338</td><td rowspan=1 colspan=1>Elecsys HE4 CalCheck 5SANran</td><td rowspan=1 colspan=1>Predicate Device:Elecsys DHEA-S CalCheck5(K103402)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The Elecsys HE4 CalCheck 5 is anassayed control for use in calibrationverification and for use in the verificationof the assay range established by theElecsys HE4 reagent on the indicatedElecsys and cobas e immunoassayanalyzers. For In Vitro Diagnostic UseOnly.</td><td rowspan=1 colspan=1>The Elecsys DHEA-S CalCheck 5 is anassayed control for use in calibrationverification and for use in theverification of the assay rangeestablished by the Elecsys DHEA-Sreagent on the indicated Elecsys andcobas e immunoassay analyzers.</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>HE4</td><td rowspan=1 colspan=1>DHEA-S</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Five</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Equine serum</td><td rowspan=1 colspan=1>Human serum</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Reconstitute Check 1, Check 2, Check 3,Check 4 and Check 5 with exactly 1.0 mLdistilled or deionized water. Allow tostand closed for 15 minutes, then mixgently by inversion.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened:•  Store at 2-8 °C up to the statedexpiration date.Reconstituted: 20-25 °C: 5 hours</td><td rowspan=1 colspan=1>Unopened:o  Store at 2-8 °C up to the statedexpiration date.Reconstituted:20-25 °C: 4 hours</td></tr></table>

Continued on next page

# 510(k) Summary

Continued

# Evaluations Summary

The Elecsys HE4 Immunoassay was evaluated for several characteristics, including precision, limit of quantitation, linearity, method comparison, interfering substances, and calibration stability.

The Elecsys HE4 CalSet, Elecsys PreciControl HE4 and HE4 CalCheck 5 were evaluated for value assignment and stability.

In addition, the Elecsys HE4 Immunoassays were evaluated in the clinical setting, completing a method comparison with clinically characterized samples, and measuring HE4 over time in subjects with ovarian cancer.

# Confidentiality

Roche Diagnostics Corporation requests that the FDA not disclose the nature or existence of the premarket notification until the substantial equivalence decision has been reached.

# Closing

We trust that the information provided in this Premarket Notification [510(k)] will support a determination of substantial equivalence for the Elecsys HE4 Test System.

If you should have questions or require further information, please do not hesitate to contact this office.

• Phone: (317) 521-3338 • FAX: (317)521-2324 jane.phillips@roche.com

Roche Diagnostics c/o Dr. Jane Phillips Regulatory Program Manager 9115 Hague Road Indianapolis, IN 46250

Re: k112624 Trade/Device Name: Elecsys HE4 Assay Elecsys HE4 CalSet Elecsys PreciControl HE4 Elecsys HE4 CalCheck 5 Regulation Number: 21 CFR $\ S 8 6 6 . 6 0 1 0$ EPY Regulation Name: Tumor-Associated Antigen Immunological Test System Regulatory Class: Class II Product Code: OIU, JIT, JJX Dated: September 14, 2012 Received: September 17, 2012

Dear Dr. Phillips:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

Page 2 - Dr. Jane Phillips

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http:/www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/9baeb67b2c79d5e39bfb3bfdb3c4c39115da1fe438ea2ea919a29c6b856ea956.jpg)

Maria M. Chan, Ph. D.   
Director   
Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

# Indications for Use Form

510(k) Number (if known): K112624

Device Name: Elecsys HE4 Assay

Indications for Use:

The Elecsys HE4 assay is an immunoassay for the quantitative determination of HE4 in human serum and plasma. The assay is used as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer. Serial testing for patient HE4 assay values should be used in conjunction with other clinical findings used for monitoring ovarian cancer.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

(Par 21h on S Subr D) AND/OR (21-Th-Coutebplase)

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/d5f2c8960fb8a2d6bdbed78c21f8142a9c924dec1988e94c366d137e6f970a15.jpg)

Divísion Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

# Indications for Use Form

510(k) Number (if known): K112624 Device Name: _ Elecsys HE4 CalSet

Indications for Use: Elecsys HE4 CalSet is used for calibrating the quantitative Elecsys HE4 assay on the Elecsys and cobas e immunoassay analyzers.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

mo

Office of In Vitro Diagnostic Device Evaluation and Safety

# Indications for Use Form

510(k) Number (if known):  _K112624

Device Name: Elecsys PreciControl HE4

Indications for Use: Elecsys PreciControl HE4 is used for quality control of the Elecsys HE4 immunoassay on Elecsys and cobas e immunoassay analyzers.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/20e30b5ba03072c2f388bc9ccc4cfc8ef33c325441ea4a08c922dcf20da2c182.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

# Indications for Use Form

510(k) Number (if known): K112624   
Device Name: Elecsys HE4 CalCheck 5

Indications for Use: The Elecsys HE4 CalCheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys HE4 reagent on the indicated Elecsys and cobas e immunoassay analyzers. For In Vitro Diagnostic Use Only.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

mon

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety